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INTRODUCTION
Allogeneic bone marrow transplantation (BMT) is cur-
rently used in the treatment of a variety of hematologic
malignant diseases and nonmalignant hematologic disor-
ders. The conventional high-dose chemotherapy and radia-
tion used to condition patients for allogeneic BMT are
highly toxic for both hematologic and nonhematologic tis-
sues. For this reason, less toxic nonmyeloablative condition-
ing regimens that result in the establishment of mixed
chimerism have become attractive. Less toxic conditioning
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ABSTRACT
Donor T-cells can provide a graft-versus-leukemia effect and help to promote donor engraftment after allogeneic
BMT; however, these benefits can be outweighed by the ability of the cells to induce life-threatening GVHD. Photo-
chemical treatment (PCT) of T-cells with S-59 psoralen and long-wavelength UV-A light can inhibit their prolifera-
tive capacity and significantly decrease their ability to induce acute GVHD after allogeneic BMT. PCT donor T-cells
have been shown to facilitate donor engraftment in a myeloablative BMT model. In this study, we examined whether
donor T-cells subjected to PCT ex vivo could retain the ability to facilitate engraftment or increase donor chimerism
after nonmyeloablative BMT or after establishment of mixed hematopoietic chimerism. In a transplantation model in
which mice were conditioned for BMT with sublethal (600 cGy) TBI, an infusion of PCT donor T-cells was unable
to facilitate engraftment of donor BM. A BMT model was used in which a mixture of allogeneic and syngeneic mar-
row cells was infused into lethally irradiated recipients for establishment of mixed hematopoietic chimerism. The
goal was to determine whether PCT donor splenocytes could increase levels of donor chimerism. Recipients of
splenocytes treated with UV-A light only (no S-59 psoralen) and given at the time of BMT or in a donor lymphocyte
infusion (DLI) had significantly higher levels of donor chimerism than did recipients of BM only. Although PCT
donor splenocytes given at the time of BMT modestly increased donor chimerism, PCT donor splenocytes given in a
DLI did not increase donor chimerism. A nonmyeloablative BMT model was employed for determining whether DLI
given relatively late after BMT could increase donor chimerism. Recipient mice were conditioned for BMT with a
combination of low-dose TBI (50 or 100 cGy) and anti-CD154 (anti-CD40L) monoclonal antibody for achievement
of low levels of mixed chimerism. When control mixed chimeras were given a DLI 71 days after BMT, donor
chimerism was significantly increased. In contrast, PCT of the donor cells eliminated the ability of the cells to
increase donor chimerism after infusion. Together results from these 3 distinct BMT models indicate that PCT of
donor T-cells significantly inhibited the ability of the cells to facilitate donor engraftment after nonmyeloablative
BMT or to increase donor chimerism in mixed hematopoietic chimeras when the cells were administered in a DLI.
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regimens allow transplantation in the care of patients who
would not be eligible to receive high-dose conditioning.
The establishment of mixed chimerism can facilitate devel-
opment of donor-host tolerance so that the patient will
more readily accept a solid organ transplant. Low levels of
donor chimerism may be sufﬁcient to correct certain hema-
tologic disorders, such as sickle cell disease and chronic
granulomatous disease [1]. In the case of hematologic malig-
nant diseases, mixed chimerism may create a setting in
which donor lymphocyte infusion (DLI) can be given later
to eradicate residual tumor and result in the conversion to
complete donor chimerism [2].
Donor T-cells given in DLI can increase donor chimerism
and provide a graft-versus-tumor (GVT) effect with a lower
risk of graft-versus-host disease (GVHD) than if given at the
time of BMT, possibly owing to immunoregulatory mecha-
nisms [3,4]. However, despite a lower incidence of severe dis-
ease, GVHD is still one of the major complications of DLI.
Thus an ongoing challenge for clinicians has been to reduce
the ability of donor T-cells to induce GVHD after BMT or
DLI yet maintain their ability to facilitate or increase donor
engraftment and mediate a GVT effect. Several strategies
have been employed in attempts to accomplish this goal,
including insertion of suicide genes [5,6], administration of
ﬁxed low numbers of donor T-cells in the BMT graft [7],
selective administration of T-cell subsets [8], incremental
DLI [9], and ex vivo γ irradiation [10]. It is still unclear
whether any one approach is superior to the others.
PCT of donor T-cells with S-59 psoralen and long-
wavelength UV-A light has been used in an experimental
BMT model to limit GVH potential without eliminating
GVT reactivity [11]. This method for controlling T-cell
reactivity is particularly attractive because it is relatively
simple and inexpensive. S-59 psoralen reversibly intercalates
DNA, but when the S-59–treated DNA is exposed to UV-A
light, covalent monadducts form. The result is cross-linked
DNA and prevention of DNA replication [12]. Cells treated
with particular concentrations of S-59 and UV-A light are
incapable of proliferating but can still express activation
markers and secrete cytokines [11]. These data suggest that
PCT donor T-cells are at least partially functional for a
period. In the current study, we examined whether a single
infusion of PCT donor cells could facilitate engraftment of
donor BM after nonmyeloablative conditioning or increase
donor chimerism in a model of mixed chimerism.
MATERIALS AND METHODS
Mice
C57BL/6 (H2b), Balb/c (H2d), B10.BR (H2k), AKR/J
(H2k), and B6.PL-Thy1a (H2b) mice 6 to 8 weeks of age were
purchased from Jackson Laboratories (Bar Harbor, ME).
The animals were housed in the Medical College of Wis-
consin Animal Resource Center or in a speciﬁc pathogen-
free facility at the University of Minnesota.
Bone Marrow Transplantation
Bone marrow (BM) was collected from the femurs and
tibias of Balb/c, C57BL/6, or B6.PL-Thy1a donors. Three
BMT models were used. In the ﬁrst, B10.BR recipients were
given a sublethal dose of 600 cGy total body irradiation
(TBI). Twenty-four hours later, the recipients were given an
intravenous (IV) injection of 107 T-depleted B6.PL-Thy1a
BM cells admixed with various numbers of PCT or control
(UV-A–treated) purified donor T-cells. The BM was
depleted of T-cells by treatment with anti-Thy1.2 murine
antibody (mAb) (clone 30-H12; American Type Culture
Collection, Manassas, VA) and complement (Accurate
Chemical and Scientific, Westbury, CT). Donor T-cells
were purified from splenocytes by negative selection after
incubation with magnet-activated cell separation (MACS)
anti-B220–conjugated magnetic beads (Milenyi Biotec,
Auburn, CA). The labeled cells were passed through MACS
columns to remove B-cells. The resulting population of
negatively selected cells comprised 80% T-cells.
In the second model, AKR/J recipients were given
1100 cGy TBI and intraperitoneal (IP) injection of a com-
bination of 200 µg anti-TCRαβ mAb (hybridoma H57-
597) and 500 µg anti-CD4 mAb (hybridoma GK1.5). One
day later, the mice were given an IV injection of a mixture
of 6 × 106 T-depleted allogeneic C57BL/6 BM and 4 × 106
T-depleted syngeneic AKR/J BM. A single infusion of 3 ×
107 PCT or control (UV-A–treated) donor B6.PL-Thy1a
splenocytes was given at the time of BMT or on day 7, 14,
or 28 posttransplantation.
In the third model, B6 recipients were given a single
dose of 50 or 100 cGy TBI. One day later, the mice were
given IV injections of 4 × 107 non–T-depleted Balb/c BM
cells. Bioreactor-derived anti-CD154 mAb (hybridoma
MR1) was administered IP (200 µg per injection) from days
–1 to 5, then twice weekly until day 14 after BMT [13]. For
DLI, chimeras were given a single IV injection of 5 × 107
PCT or control (UV-A–treated) Balb/c spleen cells.
For assessment of GVH reactivity, the recipients were
followed for body weight changes and mortality. In some
experiments, spleens collected from mice were analyzed by
ﬂow cytometry to determine CD4:CD8 ratios.
PCT of Cells
S-59 psoralen was provided by Cerus Corp. (Concord, CA)
and diluted in sterile distilled water for a stock solution of 1
µM. Splenocytes or puriﬁed T-cells were washed by centrifu-
gation and resuspended at 1 to 2 × 107/mL in phosphate-
buffered saline solution containing 5% fetal bovine serum.
S-59 was added to the cell suspensions at a ﬁnal concentra-
tion of 1 or 2 nM, and the cells were placed in 15- × 60-mm
plastic Petri dishes or 75 cm2 tissue culture ﬂasks at a vol-
ume that resulted in a ﬂuid layer of approximately 0.5 cm.
The dishes and flasks were placed on a UV-A (320-400
nm) illumination device and exposed to a dose of 3 or 4
J/cm2. The cells were washed and prepared for injection. In
some experiments, to control for light exposure, cells were
exposed to UV-A only (no S-59). In tests for PCT-induced
T-cell inactivation, PCT and non-PCT T-cells or spleno-
cytes (0.5 × 105 or 2 × 105 per well, respectively) were cul-
tured in 3 to 6 microwells containing immobilized anti-CD3
mAb (clone 145-2C11). The microwell plates were cultured
at 37°C for 3 to 4 days, and 1 µCi of 3H-thymidine was
added to each well for the ﬁnal 18 hours of culture. Stimula-
tion of the cultured cells was calculated from the amount of
3H-thymidine uptake. The combination of 1 nM S-59 plus 4
J/cm2 UV-A or 2 nM S-59 plus 3 J/cm2 UV-A typically
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resulted in 90% to 96% inactivation of T-cell proliferation
in response to CD3 cross-linking (Figure 1).
Assessment of Engraftment and Chimerism
For assessment of the engraftment status of BMT recip-
ients in the ﬁrst 2 BMT models (sublethal TBI and mixed-
chimerism lethal TBI models), recipients were euthanized at
various time points after BMT. Individual spleens were col-
lected and processed into single-cell suspensions, and the
red cells were eliminated by hypotonic lysis. The cells were
stained with combinations of fluorochrome-labeled major
histocompatibility complex (MHC) class I–specific mAb
(anti-H2Kk or anti-H2Kb) and lineage-speciﬁc mAb, includ-
ing anti-CD4, anti-CD8, anti-B220, and anti–Mac-1. In the
mixed chimerism model, donor T-cells given as DLI could
be identiﬁed by staining with a combination of donor MHC
class I mAb (anti-H2Kb) and anti-Thy1.1 mAb. All mAbs
were purchased from Pharmingen (San Diego, CA).
For chimerism analysis of mice conditioned for BMT
with nonmyeloablative TBI and anti-CD154 mAb, the mice
were bled by retroorbital venipuncture, and the mononu-
clear cells were collected after centrifugation over Ficoll
medium. The cells were stained with a combination of ﬂuo-
rochrome-labeled MHC class I–speciﬁc mAb (anti-H2b or
anti-H2d for identification of recipient and donor cells,
respectively) and lineage-specific mAbs, including anti-
CD4, anti-CD8, anti-CD19, and anti-Mac-1 (Pharmingen).
Stained cells were analyzed by flow cytometry with
FACScan or FACSCalibur ﬂow cytometers (Becton Dickin-
son, Mountain View, CA).
Statistics
Engraftment, chimerism values, and CD4:CD8 ratios
were compared with the Student t test.
RESULTS
A Single Infusion of PCT Donor Splenocytes Did Not
Increase Splenic Donor Chimerism When Given at
the Time of BMT or in DLI Soon after BMT
A BMT model was established for examining whether
PCT donor T-cells could facilitate the engraftment of
donor BM in recipients preconditioned with sublethal TBI.
B10.BR recipients were conditioned with 600 cGy TBI then
subjected to transplantation of 107 T-depleted B6.PL-Thy1a
BM cells admixed with various concentrations of PCT or
unntreated (UV-A light only) B6.PL-Thy1a T-cells. Only
1 of 15 (7%) mice given transplants of BM only had engraft-
ment of donor cells (Table 1). This mouse was a mixed
chimera with a spleen containing 40% donor cells (data not
shown). UV-A–only treated donor T-cells increased donor
engraftment in a dose-dependent manner, but mice given
1.25 to 5 × 106 donor T-cells developed GVHD as indicated
by body weight loss (data not shown) and decreased splenic
CD4:CD8 ratios (Table 1). All mice with engraftment of
donor cells, except for 1 mouse that received a dose of 0.6 ×
106 T-cells, had >90% donor cells in their spleens. The
1 mouse that had less than 90% donor cells was a mixed
chimera that had 34% donor cells in its spleen (data not
Figure 1. Photochemical inactivation of anti-CD3–induced T-cell
proliferation. Splenocytes were treated with either 1 nM S-59 plus
4 J/cm2 UV-A or 2 nM S-59 plus 3 J/cm2 UV-A and cultured on
immobilized anti-CD3 mAb for 3 to 4 days. Cell proliferation was
assessed by 3H-thymidine uptake, and the results were expressed as
counts per minute (CPM) ±SD. Data for non-PCT splenocytes
(untreated) are shown as a positive control. The graphs are representa-
tive examples of each treatment condition.
Table 1. PCT of Donor T-Cells Inhibited Their Ability to Facilitate
Engraftment of Donor BM after Nonmyeloablative Conditioning*
No. Analyzed CD4:CD8
Donor T-Cells PCT† (% Engrafted)‡ Ratio (±SD)§
None NA 15 (7%) 2.18 (0.42)
5 × 106 No 6 (100%) 0.37 (0.14)||
2.5 × 106 No 6 (100%) 0.27 (0.22)||
1.25 × 106 No 6 (83%) 0.25 (0.05)||
0.6 × 106 No 9 (56%) 1.35 (1.25)
0.3 × 106 No 9 (11%) 1.96 (1.33)
5 × 106 Yes 8 (13%) 1.80 (0.52)
2.5 × 106 Yes 8 (0%) 1.82 (0.32)
1.25 × 106 Yes 7 (0%) 1.72 (0.19)
0.6 × 106 Yes 8 (0%) 1.86 (0.50)
0.3 × 106 Yes 8 (0%) 2.13 (0.36)
*NA indicates not applicable.
†B10.BR recipient mice were conditioned for BMT by treatment
with 600 cGy TBI. Twenty-four hours later, the recipients were given
107 nucleated B6.PL-Thy1a BM cells admixed with or without the indi-
cated number of PCT (2 nM S-59 and 3 J/cm2 UV-A) or UV-A–only
treated donor T-cells.
‡Donor engraftment was assessed by flow cytometric analysis of
splenocytes stained with B-cell, T-cell, and monocyte lineage-speciﬁc
cell markers in combination with MHC class I speciﬁc markers. The
data are the combined results of mice analyzed on days 14, 30, and 100
after BMT (2-6 mice analyzed at each time point). The data were com-
bined because engraftment was stable.
§CD4:CD8 ratios were derived from splenic phenotyping done on
day 30 after BMT (3-6 mice analyzed in each group).
||P < .05 compared with the group given no donor T-cells.
B. D. Johnson et al.
584
shown). Mortality due to GVHD was observed in the
groups given 5 × 106 (50%), 2.5 × 106 (50%), and 1.25 × 106
(33%) donor UV-A–treated T-cells (data not shown).
Mice that received PCT donor T-cells did not have
engraftment with donor cells, with the exception of 1 animal
that received 5 × 106 PCT donor T-cells (Table 1). The sin-
gle mouse with engraftment had only donor cells in the
spleen (data not shown). Because facilitation of engraftment
was inhibited by PCT, not surprisingly recipients of PCT
cells did not develop GVHD as indicated by “normal”
splenic CD4:CD8 ratios (Table 1) and maintenance of body
weight above pretransplantation levels (not shown).
A model of mixed hematopoietic chimerism induced by
combined allogeneic and syngeneic BM infusion was used to
determine whether allogeneic PCT donor splenocytes could
increase donor chimerism early or later post-BMT. A strat-
egy similar to that used by Sykes et al. [14] was employed. In
our study, AKR recipients conditioned with lethal TBI and
anti-TCRαβ plus anti-CD4 mAbs were given transplants of
a 60:40 mixture of allogeneic donor and syngeneic host BM
(107 cells total). Recipients of only BM had approximately
40% donor cells in their spleens when examined 50 days
after BMT (Table 2), and all cell lineages were a mixture of
donor and host. The thymuses of these mice also contained
mixtures of donor and host cells (data not shown).
When a single infusion of 3 × 107 donor splenocytes was
given on the day of BMT or in DLI on days 7, 14, or 28
after BMT, the mice had significantly higher levels of
splenic donor chimerism than did recipients of BM only
(Table 2). Increased percentages of donor cells were also
found in the thymuses of these mice (data not shown). All
groups of mice that received an infusion of control (UV-A–
treated) donor cells appeared to have increased GVH reac-
tivity as indicated by body weight loss (Figure 2A) and
decreased lymphoid tissue cellularity (spleens and thymuses)
(data not shown). Because the infused T-cells were from
Thy1.1+ congenic donors, we could examine splenocytes on
day 50 after BMT for the presence of these cells by flow
cytometry using a combination of cell-surface markers for
Thy1.1 and donor MHC class I (H-2Kb). Significant per-
centages of infused donor T-cells (5% to 15%) could be
detected in the spleens of these mice on day 50 after BMT
(Table 2). This ﬁnding suggested that these cells were play-
ing a role in the induction of GVH reactivity.
As shown in Table 2, PCT significantly reduced the
ability of donor splenocytes given as a DLI early post-BMT
to increase donor chimerism. Donor chimerism was mod-
estly greater when PCT donor cells were given at the time
of BMT (day 0) than it was in mice given transplants of BM
only (56% versus 42%; P = .01). Although the change in
donor chimerism was increased significantly, this change
was substantially lower than that induced by non-PCT
donor T-cells. However, when PCT cells were given as
DLI, no increase in donor chimerism was observed. PCT
signiﬁcantly reduced the GVH reactivity of donor cells, as
indicated by no mortality (Table 2) and stable body weights
(Figure 2B). These mice also did not have decreased lym-
phoid tissue cellularity, as was observed in groups given
infusions of non-PCT donor cells (not shown). These data
indicated that PCT eliminated the GVH capacity of infused
donor cells, but the ability of these cells to increase donor
chimerism was signiﬁcantly decreased.
PCT Donor Spleen Cells Given in a DLI Did Not
Increase Peripheral Blood Donor Chimerism in a
BMT Model of Minimal Myeloablation
A different BMT model was used to conﬁrm results of
the previous experiments and to test whether DLI with
PCT cells at later times post-BMT could increase donor
chimerism. C57BL/6 recipients were conditioned for BMT
with a nonmyeloablative dose of TBI (50 or 100 cGy) and
anti-CD40L mAb. After transplantation with Balb/c BM,
anti-CD40L mAb treatment was continued for 2 weeks.
The B6 recipients became long-term stable mixed chimeras
Table 2. PCT of Donor Spleen Cells Inhibited Their Ability to Increase Splenic Donor Chimerism When Given at the Time of BMT or as DLI
Day of Donor-Cell % Survival No. % Allogeneic Donor % Infused Donor 
Infusion* PCT† (Day 50) Analyzed Chimerism (±SD)‡ T-Cells (±SD)§
None NA 100 9 42 (3) NA
Day 0 No 78 7 81 (17)|| 5.6 (1.6)¶
Day 7 No 63 5 91 (3)|| 5.2 (1.1)¶
Day 14 No 100 9 93 (4)|| 5.9 (2.1)¶
Day 28 No 89 8 96 (2)|| 15.1 (4.3)¶
Day 0 Yes 100 9 56 (13)|| 2.1 (0.4)¶
Day 7 Yes 100 9 39 (11) 1.4 (0.5)
Day 14 Yes 100 9 46 (15) 0.9 (0.3)
Day 28 Yes 100 8 35 (4) 1.0 (0.3)
*AKR/J recipient mice were conditioned for BMT by treatment with 1100 cGy TBI and anti-TCRαβ mAb plus anti-CD4 mAb. Twenty-four
hours later, the recipients were given 6 × 106 C57BL/6 BM cells plus 4 × 106 AKR/J BM cells.
†PCT (1 nM S-59 and 4 J/cm2 UV-A) or UV-A–only treated B6.PL-Thy1a donor spleen cells (3 × 107) were given at the indicated times.
‡Donor engraftment of allogeneic BM was assessed on day 50 after BMT by ﬂow cytometric analysis of splenocytes stained with B-cell, T-cell,
and monocyte lineage-speciﬁc cell markers in combination with an MHC class I–speciﬁc marker.
§The percentages of infused donor T-cells were determined by ﬂow cytometry after spleen cells were stained with a combination of H-2Kb-
FITC and anti-Thy1.1-PE. Background percentages (1.5% ± 0.3%) were determined from mice that received BM only (no infusion).
||Signiﬁcantly increased (P < .05) compared with the group given BM only (no donor spleen cells).
¶Signiﬁcantly increased (P < .05) compared with background (1.5 ± 0.3%).
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(Table 3) with a higher level of chimerism observed in mice
conditioned with 100 cGy TBI. A single infusion of 5 × 107
control non-PCT donor splenocytes given on day 71 after
BMT signiﬁcantly increased donor chimerism in mice that
were analyzed on days 101 and 168 after BMT (Table 3).
Mice given the DLI developed GVHD, but the GVHD was
not sufﬁciently severe to induce mortality by day 168 after
BMT (data not shown). The presence of GVHD was
reﬂected by less body weight gain after DLI than occurred
in recipients of BM only (Figure 3).
When the donor cells given as DLI were subjected to
PCT, the cells were no longer capable of increasing donor
chimerism (Table 3). Body weight gain after DLI with PCT
donor cells was less than in recipients of BM only (Figure
3), but the decreased weight gain was less than that in mice
given non-PCT DLI. The body weight curves in conjunc-
tion with the clinical appearance of the animals suggested
that GVH capacity of the donor cells, as well as chimerism-
facilitating capacity, was diminished by PCT. Although the
donor splenocytes were treated with a PCT regimen differ-
ent from that used in the ﬁrst BMT model, in which the S-59
concentration was increased and the light exposure decreased,
the level of donor T-cell inactivation, measured by prolifer-
ation in response to immobilized anti-CD3 [11], was similar
with both PCT regimens (Figure 1).
DISCUSSION
Truitt et al. previously demonstrated that PCT donor
T-cells could increase donor chimerism after myeloablative
conditioning and allogeneic BMT [11]. Similarly, Waller et
al. showed that donor lymphocytes treated with ionizing
radiation could facilitate donor engraftment without induc-
ing GVHD [10]. Their study was based on previous data that
demonstrated ionizing radiation could limit the capacity of
lymphocytes to proliferate but still allow for cytotoxic func-
tion against tumor cells [15] and preserve veto function
against host T-cells [16]. On the basis of these observations,
we hypothesized that PCT donor cells could facilitate donor
engraftment. Three different MHC-incompatible BMT
models were used to examine the ability of PCT donor cells to
increase donor chimerism. In the ﬁrst model, mice were con-
ditioned with sublethal TBI. The result was graft rejection and
autologous reconstitution unless donor T-cells were added to
the BM graft. In the second model, recipient mice were condi-
tioned with lethal TBI then subjected to transplantation with
Figure 2. PCT of donor splenocytes eliminated their capacity to cause GVH-induced body weight loss in mixed chimeras. Body weight curves for
the transplanted mice in Table 2 are shown. The data are from mice given 3  107 nontreated (UV-A) donor spleen cells (A) or PCT donor spleen
cells (B) at the time of BMT (day 0) or 7 to 28 days after BMT. Body weight curves for mice given transplants of BM alone (no spleen cells) repre-
sent GVH-negative controls.
Table 3. The Ability of Donor Cells Given as DLI to Increase Donor
Chimerism Was Inhibited after PCT
Day Percentage Donor
Post-BMT TBI* n DLI (day 71)† Chimerism (±SD)‡
57 50 cGy 30 None 10 (5)
100 cGy 29 None 27 (10)§
101 50 cGy 10 None 16 (7)
10 5 × 107 Spleen 79 (30)||
10 5 × 107 PCT spleen 23 (9)
100 cGy 9 None 42 (11)
10 5 × 107 Spleen 79 (29)||
10 5 × 107 PCT spleen 44 (16)
168 50 cGy 10 None 16 (7)
6 5 × 107 Spleen 87 (35)||
7 5 × 107 PCT spleen 19 (9)
100 cGy 9 None 43 (13)
10 5 × 107 Spleen 84 (31)||
10 5×107 PCT spleen 45 (18)
*B6 recipient mice were conditioned for BMT by treatment with
200 µg anti-CD40L mAb (days –1 to 5, then twice weekly to day 14)
and either 50 or 100 cGy total body irradiation (TBI) (day –1). For
BMT, the recipients were given 4 × 107 nucleated Balb/c BM cells.
†On day 71 posttransplantation, 5 × 107 Balb/c nontreated or PCT
spleen cells were given as DLI. For PCT, donor splenocytes were
treated with 2 mM S-59 psoralen and 3 J/cm2 UV-A light.
‡Recipients were bled at the indicated time points for assessment of
donor chimerism.
§P < .05 compared with the day 57 BM chimeras conditioned with
50 cGy.
||P < .05 compared with BM chimeras given the same conditioning
but no DLI.
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a mixture of syngeneic and allogeneic BM to achieve mixed
hematopoietic chimerism. In the third model, BM recipients
were treated with a nonmyeloablative conditioning regimen
for establishment of low-level donor chimerism (10% to
27%). Using these models, we tested whether a single infu-
sion of PCT donor cells could increase donor chimerism
when the infusion was given at the time of BMT or as a DLI
early as opposed to later after transplantation.
In the ﬁrst model (sublethal TBI with 600 cGy), non-
treated donor T-cells facilitated donor engraftment in a dose-
related fashion, but PCT donor T-cells lost the ability to
facilitate engraftment of donor BM (Table 1). In a model of
mixed chimerism, when PCT donor splenocytes were given
to recipients of mixed syngeneic/allogeneic BM at the time of
transplantation, the cells were able to modestly increase
donor chimerism in comparison with the results among mice
given transplants of BM only (Table 2). However, the level of
donor engraftment achieved by PCT donor splenocytes given
at the time of BMT was signiﬁcantly less than that obtained
by administration of non-PCT donor cells (treated with UV-A
light only). Both PCT and non-PCT donor T-cells given on
the day of BMT persisted in the spleens of infusion-treated
mice until day 50 after BMT (Table 2), but the percentage of
infused cells in the PCT group was signiﬁcantly lower (P <
.05) than that in the non-PCT group. The long-term persis-
tence of a small population of PCT donor T-cells in chimeras
that received the cells at the time of BMT is consistent with
previous data [11]. In the current study, the long-term persis-
tence of infused donor T-cells correlated with increased
donor engraftment. Together the results of these experiments
indicate that PCT of donor lymphocytes inhibits their ability
to facilitate donor engraftment.
When donor cells were given in a DLI, PCT eliminated
their ability to increase donor chimerism in 2 different
BMT models. The timing of DLI did not affect the inability
of PCT donor cells to increase donor chimerism. DLI was
given early post-BMT in 1 model (day 7–day 28 after BMT)
and late in the other model (day 71). Administration of non-
PCT DLI resulted in GVHD after administration of donor
cells, although GVHD was less severe than would be
expected if similar numbers of donor cells were given at the
time of BMT. These results were not unexpected because
previous data showed that the longer DLI is delayed after
BMT, the lower is the risk of development of GVHD [17].
PCT did have a beneficial effect in that it significantly
reduced or eliminated DLI-induced GVHD, but this effect
was not remarkable because the ability of these cells to facil-
itate engraftment was also signiﬁcantly inhibited.
The results presented here were different from those
previously reported by Truitt and coworkers [11]. We
believe the disparities are most likely due to differences in
the model systems. One explanation for the inability of
PCT donor T-cells to increase donor chimerism when given
in DLI, or when given at the time of BMT after nonmye-
loablative conditioning, may be that a single infusion of
PCT donor cells is not sufficient to overcome established
tolerance mechanisms in the DLI setting or host-versus-
graft reactivity that remains after nonmyeloablative condi-
tioning. Perhaps multiple infusions of PCT donor cells
could overcome such barriers, if present, to facilitate donor
engraftment and increase donor chimerism in our models.
The need for increasing donor chimerism after BMT
may be most relevant to the treatment of hematologic
malignant diseases in which the elimination of residual host
tumor in mixed chimeras may be needed to prevent relapse.
Previous data showed that the effect of PCT on GVT reac-
tivity was PCT regimen–dependent [11]. On the basis of
chimerism results obtained in our experiments, we would
speculate that the GVT reactivity of PCT donor cells is
diminished. It appears that PCT donor T-cells persist for
only a short time in chimeras given a DLI. We did not
detect these cells in mice that were analyzed 22 to 43 days
after DLI (Table 2). Because measurable DLI-induced GVT
responses in humans sometimes require several weeks, we
speculate that longer-term persistence of PCT donor T-cells
may be needed to achieve signiﬁcant GVT reactivity. Multi-
ple infusions of PCT lymphocytes may provide GVT reac-
tivity as well as increase donor chimerism.
In summary, PCT inhibited the ability of donor cells to
facilitate donor engraftment or increase donor chimerism
post-BMT. Perhaps larger doses of PCT donor splenocytes
or PCT CD8+ donor T-cells would be more effective at
increasing donor chimerism. Because PCT donor cells lose
their capacity to induce GVHD, multiple infusions of these
cells may be a better approach to increase donor chimerism.
Of concern is whether increased numbers of cells given as
multiple infusions would increase the risk of GVHD. The
answer may depend on how long PCT-cells are able to per-
sist in vivo. These issues need to be addressed in future
experiments.
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Figure 3. PCT of donor splenocytes given as a DLI reduced their
capacity to inhibit body weight gain in a BMT model of minimal mye-
loablation. Body weight curves are shown for the mice in Table 3 that
were given transplants. The data are expressed as body weight change
after DLI, which was administered 71 days after BMT.
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